Oxford Biomedica PLC - General Meeting

RNS Number : 9618W

Oxford Biomedica PLC

06 January 2014

 



FOR IMMEDIATE RELEASE

OXFORD BIOMEDICA PLC

GENERAL MEETING

Oxford, UK - 6 January 2014: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London.  In accordance with Listing Rule 9.6.18, the following resolution was passed at the meeting:

Resolution 1: THAT, the entry by the Company into the proposed secured Loan Facility of up to £5 million with Vulpes Life Sciences Fund, being a related party transaction for the purposes of the Listing Rules, be and is hereby approved.

The full text of the Shareholder Circular and the Notice of Meeting can be viewed by visiting the Company's website at www.oxfordbiomedica.co.uk.

Certified copies of the document setting out the above resolution passed at this General Meeting have been submitted to the National Storage Mechanism and will shortly be available for inspection at: www.Hemscott.com/nsm.do.

The results of the proxy voting in advance of the meeting are shown below.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
1	331,276,628	1,016,145	981,574	718,232	716,075	334,708,654	Approved

-Ends-

For further information, please contact:
Oxford BioMedica plc: Tim Watts, Chief Financial Officer	Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

ROMUGUQPGUPCGUQ